Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 7/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18381606 | 0.83 | LOXL2 (0.50) | LOXL2CYP2A6TAAR1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL20508979 | 0.81 | LOXL2 (0.48) | LOXL2CYP2A6TAAR1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL20497353 | 0.78 | LMNA (0.49) | LOXL2NOS3NOS1NOS2 | |
| SCHEMBL12523289 | 0.77 | NPC1 (0.46) | CYP2A6TAAR1 | |
| SCHEMBL3543404 | 0.77 | VHL (0.48) | NOS3NOS1 | |
| SCHEMBL3542048 | 0.77 | CHRM1 (0.38) | — | |
| SCHEMBL12844556 | 0.74 | MGLL (0.48) | — | |
| SCHEMBL27256613 | 0.74 | CYP1A2 (0.46) | LOXL2HRH3ABATTAAR1 | |
| SCHEMBL3706685 | 0.73 | MAPT (0.45) | — | |
| SCHEMBL23514708 | 0.72 | PTGS1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107674037-A | The method of one kind 5 methyl 2 (triazoles of 2H 1,2,3) benzoic acid of synthesis | 四川大学 | 2018-02-09 | — | — | CN | claimed |
| CN-107573294-A | The synthetic method of 5 methyl 2 (base of 1,2,3 triazoles of 2H 2) benzoic acid | 四川大学 | 2018-01-12 | — | — | CN | claimed |
| EP-4618974-A1 | OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025129135-A2 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024107615-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| CN-114702495-A | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-108473495-B | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| WO-2017048962-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| CN-101128439-A | 1,6 - substituted (3r,6r) -3- (2,3-dihydro-1h-inden-2-yl)-2,5-piperazinedione derivatives as oxytocin receptor antagonists for the treatment of pre-term labour, dysmenorrhea and endometriosis | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | CN | disclosed |
| EP-1831183-A1 | 1,6-SUBSTITUTED (3R,6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067462-A1 | 1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | OXTR, OPRL1, GPER1 | LOXL2 3440/4885HRH3 927/4885ADRB2 85/4885 |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | LOXL2 2605/4885HRH3 1870/4885ADRB2 3892/4885 |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | LOXL2 2605/4885HRH3 1870/4885ADRB2 3892/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | LOXL2 2605/4885HRH3 1870/4885ADRB2 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.